"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 2 | 3 |
| 2004 | 6 | 3 | 9 |
| 2005 | 0 | 3 | 3 |
| 2006 | 4 | 3 | 7 |
| 2007 | 5 | 2 | 7 |
| 2008 | 4 | 2 | 6 |
| 2009 | 6 | 2 | 8 |
| 2010 | 2 | 3 | 5 |
| 2011 | 4 | 3 | 7 |
| 2012 | 8 | 3 | 11 |
| 2013 | 6 | 3 | 9 |
| 2014 | 3 | 2 | 5 |
| 2015 | 8 | 0 | 8 |
| 2016 | 3 | 3 | 6 |
| 2017 | 1 | 2 | 3 |
| 2018 | 3 | 2 | 5 |
| 2019 | 3 | 0 | 3 |
| 2020 | 5 | 0 | 5 |
| 2021 | 3 | 1 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
| 2025 | 4 | 1 | 5 |
| 2026 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). Metabolism. 2015 Oct; 64(10):1359-71.
-
Genetic analysis of 16 NMR-lipoprotein fractions in humans, the GOLDN study. Lipids. 2013 Feb; 48(2):155-65.
-
Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network. Nutr Metab Cardiovasc Dis. 2013 Oct; 23(10):987-94.
-
Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate. PLoS One. 2012; 7(10):e48663.
-
Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate. Pharmacogenet Genomics. 2012 Oct; 22(10):750-7.
-
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011 Jul; 96(7):2236-47.
-
Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia? Metab Syndr Relat Disord. 2011 Jun; 9(3):163-5.
-
Lipid management in clinical practice. Curr Opin Lipidol. 2009 Aug; 20(4):350-2.
-
Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem. 2006 Nov; 52(11):2036-42.
-
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006 Nov; 91(11):4489-96.